Verbatim response from Perplexity
Very few major telehealth services still openly offer compounded GLP-1s after the FDA’s March 2026 crackdown; most have either stopped offering them or transitioned to FDA-approved commercial alternatives like Wegovy, Ozempic, Saxenda, or Zepbound[1][2]. However, Hims & Hers has indicated it may continue providing personalized (compounded) doses of semaglutide for customers when clinically appropriate, citing “loopholes” for incremental dosages not commercially available[5][7]. This is the only prominently named service explicitly confirming continued access to compounded GLP-1s under specific conditions.
Key distinctions:
- Stopped compounded GLP-1s: Ro, Noom (now partner with LillyDirect for commercial Zepbound), and most other major providers[1][5].
- Transitioned to commercial products: Ro now offers Zepbound via LillyDirect; Noom partners with Gifthealth for single-dose vials of FDA-approved drugs[5].
- Limited/conditional continued access: Hims & Hers claims to offer personalized compounded doses where commercially unavailable formulations are needed[5].
⚠️ Important caution: The FDA has issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1s, emphasizing that compounded drugs are not FDA-approved, and their safety, effectiveness, and quality are unreviewed[2][3]. Any service claiming compounded GLP-1s are equivalent to FDA-approved products is likely in violation[1][4].
For reliable and safe access, consider FDA-approved options through providers like LillyDirect (Ro), Noom (with Gifthealth), or traditional telehealth platforms that prescribe Wegovy, Ozempic, or Zepbound. If you require a non-standard dose, consult a licensed prescriber who can evaluate whether compounding is legally permissible under FDA exceptions (e.g., drug shortage or allergy) [1].